Ocugen Reports 2027 Clinical Readout Expectations and Going-Concern Disclosures

Ocugen expects pivotal clinical trial readouts in 2027. Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing financial constraints related to share conversions. The company also said its inhaled COVID-19 vaccine candidate, OCU500, entered a NIAID-conducted and funded Phase 1 trial in the second quarter of 2026.